+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Non-Invasive Cancer Detection Market by Technology (Breath Analysis, Imaging, Optical Detection), Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer), End User, Product - Global Forecast 2025-2030- Product Image
Non-Invasive Cancer Detection Market by Technology (Breath Analysis, Imaging, Optical Detection), Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer), End User, Product - Global Forecast 2025-2030- Product Image
Sale

Non-Invasive Cancer Detection Market by Technology (Breath Analysis, Imaging, Optical Detection), Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer), End User, Product - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6123227
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
In recent years, non-invasive cancer detection technologies have transitioned from niche research endeavors to central pillars of precision medicine. These innovations are fundamentally reshaping early diagnostic pathways, reducing patient burden, and improving longitudinal monitoring of malignancies. As patient comfort and clinical efficiency take precedence, the integration of breath, imaging, optical, saliva, and urine analysis methods is becoming increasingly seamless, driving cross-disciplinary collaboration between engineers, clinicians, and data scientists.

This introduction establishes the significance of non-invasive approaches in oncology care delivery. By minimizing procedural risks and enhancing patient compliance, these techniques are poised to alleviate long-standing challenges associated with biopsy-based diagnostics. Moreover, the convergence of sensor miniaturization, advanced imaging modalities, and molecular assays is unlocking new frontiers in early detection, thereby setting the stage for transformative improvements in survival outcomes and healthcare resource optimization.

Charting the Major Transformative Shifts in Non-Invasive Cancer Detection Technologies Fueled by Breakthroughs in Imaging, Biosensing, and Molecular Analysis Capabilities

The landscape of non-invasive cancer detection is undergoing transformative shifts driven by breakthroughs in biosensor technology, imaging resolution, and molecular analytics. As sensor-based and volatile organic compound breath analysis achieve higher specificity, concurrently advancing CT, MRI, PET/CT, and ultrasound applications benefit from AI-enabled image reconstruction and pattern recognition. These parallel developments are converging to create hybrid diagnostic protocols that blend functional and structural assessment in real time.

Optical detection methods, including biofluorescence and infrared imaging, are also scaling rapidly, complementing liquid biopsy approaches in saliva and urine through refined biomarker and genetic assays. This synergy is strengthening multidimensional screening strategies, enabling earlier intervention. Looking ahead, the emergence of integrated platforms that unify data from these disparate technologies promises to accelerate clinical adoption, underpinning a next generation of personalized oncology workflows.

Exploring the Cumulative Impact of Newly Implemented United States Tariffs on Non-Invasive Cancer Detection Equipment, Reagents, and Consumable Supply Chains

The introduction of new United States tariffs in 2025 has created a complex web of cost pressures and supply chain realignments for manufacturers of non-invasive cancer detection equipment and consumables. Initially, sensor device producers importing analytical instruments and imaging systems have faced elevated duty rates, resulting in the need to reevaluate sourcing strategies. As a consequence, several vendors are exploring domestic production partnerships to mitigate tariff exposure, while others have adjusted their pricing models to maintain margin integrity.

Moreover, the reagents and test kits essential for saliva and urine analysis have seen cost escalations that reverberate through diagnostic laboratories and hospital networks. This shift has prompted healthcare providers to negotiate long-term agreements, seek alternative suppliers, and optimize test utilization protocols. In parallel, imaging system providers leveraging components from tariff-affected regions are diversifying their component sourcing to maintain technology roadmaps without compromising innovation timelines.

Despite these challenges, the cumulative impact of tariffs has also catalyzed strategic realignments that may yield long-term resilience. Regional manufacturing hubs are gaining momentum, and collaborative frameworks between instrument makers, reagent suppliers, and clinical end users are taking shape. Transitioning to multi-sourcing models and pursuing tariff-driven R&D incentives are emerging as critical strategies to ensure uninterrupted access to cutting-edge detection tools throughout 2025 and beyond.

Deriving Strategic Market Insights Through Comprehensive Technology, Cancer Type, End User, and Product Segmentation to Inform Targeted Growth Strategies

Market segmentation offers a nuanced understanding of where non-invasive cancer detection solutions generate the greatest value. From a technology standpoint, breath analysis techniques-spanning sensor-based detection and volatile organic compound profiling-are carving out roles in early screening, while high-resolution imaging modalities such as CT, MRI, PET/CT, and ultrasound continue to dominate structural assessments. Optical detection through biofluorescence and infrared imaging layers functional insights atop these structural views, and advances in saliva and urine analysis leverage biomarker and genetic tests to deliver reproducible molecular intelligence.

Cancer type segmentation further illustrates distinct adoption curves: breast cancer protocols benefit from multi-modality screening regimens, while colorectal detection is gaining traction through non-invasive stool and breath assays. Lung cancer initiatives combine imaging scans with breath biomarker panels, and prostate cancer monitoring is enhanced by urinary genetic markers. End-user segmentation reveals that diagnostic laboratories remain pivotal hubs for assay-driven services, ambulatory care centers are integrating point-of-care solutions for rapid screening, hospitals deploy comprehensive platforms for in-hospital diagnostics, and research institutes pilot next-generation probes. Finally, product segmentation distinguishes consumables-which include reagents and test kits-from instruments, encompassing analytical instruments, imaging systems, and sensor devices, each demanding tailored regulatory and supply strategies.

Revealing Critical Regional Dynamics in Americas, Europe Middle East Africa, and Asia-Pacific That Are Shaping the Global Adoption of Non-Invasive Cancer Detection Modalities

Regional dynamics underscore how infrastructure maturity, regulatory frameworks, and healthcare priorities shape non-invasive cancer detection adoption. In the Americas, advanced reimbursement models and established clinical networks accelerate uptake of imaging systems, sensor devices, and high-throughput genetic assays. Conversely, emerging markets within the region are focusing investments on cost-effective consumables and portable point-of-care platforms to broaden early screening.

In the Europe, Middle East & Africa landscape, stringent regulatory pathways ensure solution efficacy and safety, prompting vendors to invest in robust clinical validation studies. Collaborative consortia spanning multiple countries are galvanizing harmonized approval processes, which in turn facilitate cross-border sales of diagnostic platforms. In Asia-Pacific, government-led funding initiatives coupled with expanding healthcare infrastructure are driving rapid acceptance of breath, saliva, and urine assays. Localized manufacturing partnerships and public-private collaborations are also enhancing accessibility to advanced imaging and biosensing modalities across diverse socioeconomic contexts.

Illuminating the Competitive Landscape by Highlighting Leading Key Companies Driving Innovation, Partnerships, and Market Leadership in Non-Invasive Cancer Detection

The competitive landscape is defined by companies that bring together multidisciplinary expertise in diagnostics, imaging, and molecular biology. Leading firms are differentiating through strategic alliances with technology innovators, leveraging joint development agreements to integrate AI-driven analytics into imaging platforms. Others are forging partnerships with academic centers to co-develop novel biomarkers for breath and optical detection, thereby expanding their portfolios beyond traditional modalities.

Further consolidation is evident as established instrument manufacturers acquire niche sensor device startups, creating end-to-end solutions that encompass analytical instruments, imaging systems, and consumables. Meanwhile, reagent and test kit specialists are enhancing assay sensitivity and specificity through proprietary antibody and nucleic acid chemistries. Collectively, these ecosystem players are shaping the market’s competitive contours by prioritizing scale, regulatory excellence, and a broad technology suite capable of addressing diverse oncology screening and monitoring applications.

Delivering Actionable Strategic Recommendations for Industry Leaders to Capitalize on Emerging Opportunities and Navigate Challenges in Non-Invasive Cancer Detection

To thrive amid evolving technology and policy environments, industry leaders should prioritize investments in sensor miniaturization and AI-enabled imaging analytics. By fostering collaborative research initiatives that unite clinical experts with data scientists, organizations can accelerate the validation of novel biomarkers across breath, saliva, and urine assays. Simultaneously, establishing flexible manufacturing capabilities-both domestically and in low-cost regions-will help mitigate tariff-related cost pressures and ensure supply chain resilience.

Furthermore, aligning market entry strategies with regional regulatory and reimbursement landscapes is critical. Engaging proactively with health authorities to streamline approval pathways and participating in value-based care pilots can expedite adoption. On the commercial front, developing outcome-driven service models that bundle instruments, consumables, and analytic services will strengthen customer loyalty. Finally, leveraging real-world evidence generated through partnerships with hospitals and research institutes can substantiate clinical value propositions, supporting both market penetration and long-term revenue growth.

Detailing the Rigorous Research Methodology Underpinning the Market Study to Provide Transparency on Data Collection, Analysis Techniques, and Validation Processes

This market research report is underpinned by a rigorous mixed-method research methodology designed to ensure data accuracy and actionable insights. Primary research included in-depth interviews with key stakeholders, such as clinical oncologists, laboratory directors, procurement specialists, and technology developers, to validate market drivers, challenges, and innovation trajectories. Secondary research encompassed an extensive review of peer-reviewed journals, regulatory filings, patents, and industry white papers to triangulate findings and contextualize technology trends.

Quantitative analysis involved segmenting data by technology, cancer type, end user, and product category, followed by data cleaning and normalization processes to ensure consistency. Market dynamics were analyzed through supply chain mapping, competitive benchmarking, and tariff impact assessments. Validation workshops with domain experts provided further robustness. All data sources and methodological steps are documented in the full report, offering transparency into assumptions, limitations, and the analytical framework that supports strategic decision-making.

Concluding Insights Summarizing the Critical Findings, Strategic Implications, and Future Outlook for Non-Invasive Cancer Detection Market Evolution

This executive summary has synthesized the evolution of non-invasive cancer detection from an emerging concept to a cornerstone of precision medicine. Through an examination of transformative technology shifts, tariff-driven supply chain realignments, and in-depth segmentation insights, the report highlights critical inflection points guiding market progression. Regional analyses underscore how differing regulatory and infrastructure landscapes influence adoption, while competitive mapping reveals the strategies of companies striving for leadership.

By consolidating these multifaceted perspectives and offering actionable recommendations, this research frames a clear path for stakeholders to invest, innovate, and navigate complex policy environments. Ultimately, the integration of advanced diagnostics across breath, imaging, optical, saliva, and urine platforms promises to enhance early detection, patient outcomes, and healthcare sustainability. The full report delves deeper into each aspect, equipping decision-makers with the comprehensive intelligence required to seize emerging opportunities.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Technology
    • Breath Analysis
      • Sensor-Based Detection
      • VOC Analysis
    • Imaging
      • CT
      • MRI
      • PET/CT
      • Ultrasound
    • Optical Detection
      • Biofluorescence
      • Infrared Imaging
    • Saliva Analysis
      • Biomarker Tests
      • Genetic Tests
    • Urine Analysis
      • Biomarker Tests
      • Genetic Tests
  • Cancer Type
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Prostate Cancer
  • End User
    • Ambulatory Care Centers
    • Diagnostic Laboratories
    • Hospitals
    • Research Institutes
  • Product
    • Consumables
      • Reagents
      • Test Kits
    • Instruments
      • Analytical Instruments
      • Imaging Systems
      • Sensor Devices
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories
  • Illumina Inc.
  • QIAGEN N.V.
  • Exact Sciences Corporation
  • Guardant Health Inc.
  • Natera Inc.
  • Myriad Genetics Inc.
  • GRAIL Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid advances in liquid biopsy assays enabling early multi-cancer detection through circulating tumor DNA
5.2. Integration of AI-driven image analysis with liquid biopsy results for personalized non-invasive cancer screening
5.3. Development of high-sensitivity exosome-based biomarkers for blood-based detection of early-stage solid tumors
5.4. Emergence of multi-omic panels combining epigenetic, proteomic, and metabolomic signals for pan-cancer screening
5.5. Expansion of point-of-care digital droplet PCR platforms for real-time oncology screening in primary care settings
5.6. Strategic partnerships between diagnostics firms and academic research centers to clinically validate novel tumor cfDNA markers in large population cohorts
5.7. Regulatory approvals for next-generation non-invasive colorectal and lung cancer screening tests driven by recent trial data
5.8. Deployment of wearable biosensor patches monitoring circulating tumor biomarkers for continuous cancer surveillance in high-risk patients
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Non-Invasive Cancer Detection Market, by Technology
8.1. Introduction
8.2. Breath Analysis
8.2.1. Sensor-Based Detection
8.2.2. VOC Analysis
8.3. Imaging
8.3.1. CT
8.3.2. MRI
8.3.3. PET/CT
8.3.4. Ultrasound
8.4. Optical Detection
8.4.1. Biofluorescence
8.4.2. Infrared Imaging
8.5. Saliva Analysis
8.5.1. Biomarker Tests
8.5.2. Genetic Tests
8.6. Urine Analysis
8.6.1. Biomarker Tests
8.6.2. Genetic Tests
9. Non-Invasive Cancer Detection Market, by Cancer Type
9.1. Introduction
9.2. Breast Cancer
9.3. Colorectal Cancer
9.4. Lung Cancer
9.5. Prostate Cancer
10. Non-Invasive Cancer Detection Market, by End User
10.1. Introduction
10.2. Ambulatory Care Centers
10.3. Diagnostic Laboratories
10.4. Hospitals
10.5. Research Institutes
11. Non-Invasive Cancer Detection Market, by Product
11.1. Introduction
11.2. Consumables
11.2.1. Reagents
11.2.2. Test Kits
11.3. Instruments
11.3.1. Analytical Instruments
11.3.2. Imaging Systems
11.3.3. Sensor Devices
12. Americas Non-Invasive Cancer Detection Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Non-Invasive Cancer Detection Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Non-Invasive Cancer Detection Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. F. Hoffmann-La Roche Ltd
15.3.2. Thermo Fisher Scientific Inc.
15.3.3. Abbott Laboratories
15.3.4. Illumina Inc.
15.3.5. QIAGEN N.V.
15.3.6. Exact Sciences Corporation
15.3.7. Guardant Health Inc.
15.3.8. Natera Inc.
15.3.9. Myriad Genetics Inc.
15.3.10. GRAIL Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. NON-INVASIVE CANCER DETECTION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 6. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC NON-INVASIVE CANCER DETECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC NON-INVASIVE CANCER DETECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. NON-INVASIVE CANCER DETECTION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. NON-INVASIVE CANCER DETECTION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. NON-INVASIVE CANCER DETECTION MARKET: RESEARCHAI
FIGURE 24. NON-INVASIVE CANCER DETECTION MARKET: RESEARCHSTATISTICS
FIGURE 25. NON-INVASIVE CANCER DETECTION MARKET: RESEARCHCONTACTS
FIGURE 26. NON-INVASIVE CANCER DETECTION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. NON-INVASIVE CANCER DETECTION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SENSOR-BASED DETECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SENSOR-BASED DETECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY VOC ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY VOC ANALYSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CT, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CT, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY MRI, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY MRI, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PET/CT, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PET/CT, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BIOFLUORESCENCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BIOFLUORESCENCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INFRARED IMAGING, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INFRARED IMAGING, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BIOMARKER TESTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BIOMARKER TESTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY GENETIC TESTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BIOMARKER TESTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BIOMARKER TESTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY GENETIC TESTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY REAGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TEST KITS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TEST KITS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY ANALYTICAL INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY ANALYTICAL INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SENSOR DEVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SENSOR DEVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS NON-INVASIVE CANCER DETECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES NON-INVASIVE CANCER DETECTION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 143. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 144. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 145. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2018-2024 (USD MILLION)
TABLE 146. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2025-2030 (USD MILLION)
TABLE 147. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
TABLE 148. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2025-2030 (USD MILLION)
TABLE 149. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2018-2024 (USD MILLION)
TABLE 150. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2025-2030 (USD MILLION)
TABLE 151. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2018-2024 (USD MILLION)
TABLE 152. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2025-2030 (USD MILLION)
TABLE 153. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, 2018-2024 (USD MILLION)
TABLE 154. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, 2025-2030 (USD MILLION)
TABLE 155. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 156. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 157. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 160. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 161. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 162. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 163. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 164. CANADA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 165. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 166. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 167. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2018-2024 (USD MILLION)
TABLE 168. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2025-2030 (USD MILLION)
TABLE 169. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
TABLE 170. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2025-2030 (USD MILLION)
TABLE 171. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2018-2024 (USD MILLION)
TABLE 172. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2025-2030 (USD MILLION)
TABLE 173. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2018-2024 (USD MILLION)
TABLE 174. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2025-2030 (USD MILLION)
TABLE 175. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, 2018-2024 (USD MILLION)
TABLE 176. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, 2025-2030 (USD MILLION)
TABLE 177. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 178. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 179. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 182. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 183. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 184. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 185. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 186. MEXICO NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE CANCER DETECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 256. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2018-2024 (USD MILLION)
TABLE 258. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 274. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 276. UNITED KINGDOM NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 277. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 278. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 279. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2018-2024 (USD MILLION)
TABLE 280. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2025-2030 (USD MILLION)
TABLE 281. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
TABLE 282. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2025-2030 (USD MILLION)
TABLE 283. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2018-2024 (USD MILLION)
TABLE 284. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2025-2030 (USD MILLION)
TABLE 285. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2018-2024 (USD MILLION)
TABLE 286. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2025-2030 (USD MILLION)
TABLE 287. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, 2018-2024 (USD MILLION)
TABLE 288. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY URINE ANALYSIS, 2025-2030 (USD MILLION)
TABLE 289. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 290. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 291. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 294. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 295. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 296. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 297. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 298. GERMANY NON-INVASIVE CANCER DETECTION MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 299. FRANCE NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 300. FRANCE NON-INVASIVE CANCER DETECTION MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 301. FRANCE NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2018-2024 (USD MILLION)
TABLE 302. FRANCE NON-INVASIVE CANCER DETECTION MARKET SIZE, BY BREATH ANALYSIS, 2025-2030 (USD MILLION)
TABLE 303. FRANCE NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
TABLE 304. FRANCE NON-INVASIVE CANCER DETECTION MARKET SIZE, BY IMAGING, 2025-2030 (USD MILLION)
TABLE 305. FRANCE NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2018-2024 (USD MILLION)
TABLE 306. FRANCE NON-INVASIVE CANCER DETECTION MARKET SIZE, BY OPTICAL DETECTION, 2025-2030 (USD MILLION)
TABLE 307. FRANCE NON-INVASIVE CANCER DETECTION MARKET SIZE, BY SALIVA ANALYSIS, 2018-2024 (USD MILLION)
TABLE 308. FRANCE NON-INVASIVE CANC

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Non-Invasive Cancer Detection market report include:
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories
  • Illumina Inc.
  • QIAGEN N.V.
  • Exact Sciences Corporation
  • Guardant Health Inc.
  • Natera Inc.
  • Myriad Genetics Inc.
  • GRAIL Inc.

Related Reports

Non-Invasive Cancer Diagnostics - Global Strategic Business Report - Product Image

Non-Invasive Cancer Diagnostics - Global Strategic Business Report

  • Report
  • 385 Pages
  • Global
From
Non-Invasive Liquid Biopsy Market by Technology (Digital PCR, Next Generation Sequencing, Quantitative PCR), Application (Cancer Screening, Infectious Disease Diagnostics, Prenatal Testing), Biomarker, End User - Global Forecast 2025-2030 - Product Image

Non-Invasive Liquid Biopsy Market by Technology (Digital PCR, Next Generation Sequencing, Quantitative PCR), Application (Cancer Screening, Infectious Disease Diagnostics, Prenatal Testing), Biomarker, End User - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Global Liquid Biopsy Market 2018-2035: Distribution by Application, Target Disease Indication, Type of Circulating Biomarker, Type of Sample, End-users, Stage of Development, Type of Product, Type of Technique, Application Area and Key Geographical Regions - Product Image

Global Liquid Biopsy Market 2018-2035: Distribution by Application, Target Disease Indication, Type of Circulating Biomarker, Type of Sample, End-users, Stage of Development, Type of Product, Type of Technique, Application Area and Key Geographical Regions

  • Report
  • 331 Pages
  • Global
From
Single Cancer Screening Market by Cancer Type (Breast, Cervical, Colorectal), Technology (AI Based Tools, Endoscopy, Genomic), End User, Screening Method, Distribution Channel - Global Forecast 2025-2030 - Product Image

Single Cancer Screening Market by Cancer Type (Breast, Cervical, Colorectal), Technology (AI Based Tools, Endoscopy, Genomic), End User, Screening Method, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Spain Liquid Biopsy Market Competition Forecast & Opportunities, 2028 - Product Image

Spain Liquid Biopsy Market Competition Forecast & Opportunities, 2028

  • Report
  • 78 Pages
  • Spain
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.